March 19, 2019 Latest News Aggregator

Merck gets Canadian CRISPR Nickase Patent

Merck, a leading science and technology company and leader in genome editing has announced that the Canadian Patent Office has allowed Merck’s patent application directed to the use of paired CRISPR nickases in eukaryotic cells. The patent provides an important and more specific solution for scientists who need accurate methods when developing treatments for difficult-to-treat diseases that ultimately reach the patient.

Merck’s CRISPR patent in Canada covers foundational genome-editing technology that improves CRISPR’s ability to fix diseased genes while not affecting healthy ones

“This patent allowance marks another advancement in safety for CRISPR-enabled therapeutics, as it covers technology that improves CRISPR’s ability to fix diseased genes while not affecting healthy ones,” said Udit Batra, member of the Merck Executive Board and CEO, Life Science. “Merck has been at the forefront of genome-editing innovation for 15 years and this allowance further expands our foundational CRISPR cutting and integration intellectual property to help scientists advance gene therapy research.”

CRISPR technology is a core competency for Merck. The company supports research with genome editing under careful consideration of ethical and legal standards. Merck has established an independent, external Bioethics Advisory Panel to provide guidance for research in which its businesses are involved, including research on or using genome editing, and has defined a clear operational position taking into account scientific and societal issues to inform promising therapeutic approaches for use in research and applications.

This Canadian patent marks Merck’s second in Canada and the 13th worldwide. Similar patents were granted in Australia and Europe in late 2018. This latest patent covers paired nickases, which drive specificity through a highly flexible and efficient approach to reduce off-target effects.

Paired nickases are two CRISPR nickases targeted to a common gene target that work together by nicking or cleaving opposite strands of a chromosomal sequence to create a double-stranded break. This process can include an exogenous or donor sequence for insertion in the same manner as Merck’s CRISPR integration technology. The requirement of two CRISPR binding events greatly reduces the chances of off-target cutting at other locations in the genome.

Merck’s CRISPR integration patent portfolio includes granted patents in Australia, Canada, China, Europe, Israel, Singapore and South Korea. These CRISPR patents are for chromosomal integration or cutting of the sequence of eukaryotic cells and insertion of a DNA sequence, to make a desired genomic change.

Merck is licensing its entire patent portfolio for all fields of use.

Merck was the first company to offer custom biomolecules for genome editing globally (TargeTron™ RNA-guided group II introns and CompoZr™ zinc finger nucleases), driving adoption of these techniques by researchers all over the world. Merck was also the first to manufacture arrayed CRISPR libraries covering the entire human genome, accelerating disease cures by allowing scientists to explore more questions about root causes.

In addition to basic genome-editing research, Merck supports development of gene- and cell-based therapeutics and manufactures viral vectors. The Life Science business of Merck has a dedicated genome-editing group aimed at advancing research in novel modalities — from genome editing to gene medicine manufacturing — further solidifying the company’s commitment to the field.

Read: Glenmark announces Q3 FY 2019 results

in Market
Related Posts

Gold slips below Rs 34,000 on weak global cues

March 2, 2019

March 2, 2019

New Delhi, Mar 2 (PTI) Gold prices fell by Rs 310 to Rs 33,770 per 10 grams at the bullion...

Sensex Jumps Over 250 Points, Nifty Hits 10,870

March 1, 2019

March 1, 2019

Domestic stock markets started Friday’s session on a strong note tracking gains in Asian peers, a day after official data...

Bharti Airtel Board Approves Plan To Raise Rs. 32,000 Crore

March 1, 2019

March 1, 2019

MUMBAI: Telecom major Bharti Airtel on Thursday said its board of directors has approved fund raising up to Rs. 32,000...

Ravneet Gill takes charge as Yes Bank MD, CEO

March 2, 2019

March 2, 2019

New Delhi, Mar 1 (PTI) Yes Bank Friday said Ravneet Gill has taken charge as its MD and CEO with...

Wockhardt receives USFDA nod for Prostate Cancer Drug

March 1, 2019

March 1, 2019

Pharmaceutical and biotechnology major Wockhardt has received approval from the United States Food & Drug Administration (US FDA) for an...

Life Biosciences appoints Dr. Mehmood Khan as CEO

March 5, 2019

March 5, 2019

Life Biosciences Inc. has announced Dr. Mehmood Khan, former PepsiCo Vice Chairman and Chief Scientific Officer, is incoming Chief Executive...

SBI Reports Frauds Of Rs. 7,951 Crore In April-December Of FY19

March 2, 2019

March 2, 2019

State Bank of India (SBI) said on Friday it had reported frauds amounting Rs. 7,951 crore during the first nine...

Sensex turns negative, falls over 50 points in cautious trade; Nifty trades below 10,800-mark

February 28, 2019

February 28, 2019

Mumbai: Reversing its initial recovery, the benchmark BSE Sensex slipped into the negative terrain in afternoon trade on Thursday amid...

Crude oil prices to trade firm on falling oil supply

March 2, 2019

March 2, 2019

Precious metals closed the week with negative gains after the US reported strong economic data leading to a strong dollar....

Prashant Nagre, CEO, Fermenta Biotech receives Best CEO of the Year Award

March 5, 2019

March 5, 2019

The Pride of Maharashtra Award 2018 was presented by Dr Raghunath Mashelkar, President, Global Research Alliance & Former Director General,...

Jet Airways Founder Naresh Goyal Agrees To Step Down As Chairman: Report

March 1, 2019

March 1, 2019

Jet Airways’ founder Naresh Goyal has agreed to step down as chairman of the airline’s board, two sources with direct...

Renault’s new CEO reiterates commitment to alliance partnership

March 5, 2019

March 5, 2019

PARIS (Reuters) – Renault’s new CEO, Thierry Bollore, reiterated on Tuesday that all the parties in the Renault-Nissan-Mitsubishi alliance were...

Sensex Rises Over 90 Points As Markets Recover Early Losses: 10 Things To Know

March 5, 2019

March 5, 2019

Domestic stock markets recovered early losses shrugging off weakness in Asian peers. The Sensex rose as much as 90.41 points...

Growth In India’s Housing Prices Likely To Slow To 1.3% This Year: Poll

March 5, 2019

March 5, 2019

Housing prices in India will barely rise this year as a slowing economy and a liquidity crisis keep buyers on...

Glenmark announces Q3 FY 2019 results

March 5, 2019

March 5, 2019

Glenmark Pharma has announced its financial results for the third quarter ended December 31 of the financial year 2018-19. In...